Objectives To assess the efficacy of golimumab in combination with methotrexate (MTX) versus
MTX monotherapy in psoriatic arthritis (PsA) dactylitis. Methods Multicentre, investigator-…

Background Axial spondyloarthritis (axSpA), particularly ankylosing spondylitis was
historically considered a male's disease and has been under-recognized in women. Emerging …

Objective. To assess longterm effectiveness of tumor necrosis factor inhibitors (TNFi) in patients
with psoriatic arthritis (PsA) registered in the Rheumatic Diseases Portuguese Register, …

Background Comedication with conventional synthetic disease-modifying antirheumatic drugs
(csDMARDs) during treatment with tumour necrosis factor inhibitors (TNFi) is extensively …

Objective: To update the recommendations for the treatment of axial spondyloarthritis (axSpA)
with biological therapies, endorsed by the Portuguese Society of Rheumatology. Methods: …

Objectives Many axial spondylarthritis (axSpA) patients receive a conventional synthetic
DMARD (csDMARD) in combination with a TNF inhibitor (TNFi). However, the value of this co-…

Background: biosimilars are similar versions of existing innovator biologic agents but with
distinct manufacturing processes. They were approved in inflammatory bowel disease (IBD) by …

Background Hepatitis B virus (HBV) vaccination is recommended for non-immunised
patients with rheumatic diseases starting biological disease-modifying antirheumatic drugs (…

Psoriatic arthritis (PsA) is a chronic inflammatory rheumatic disease with a broad clinical
spectrum. PsA can affect the axialskeleton, peripheral joints, entheses, synovial sheaths of …

Objective To compare outcomes in psoriatic arthritis (PsA) patients initiating adalimumab (ADA),
with short-and long-term disease duration and to evaluate the potential effect of …